Biodesix Announces Publication of a New Nodify CDT® Clinical Validation Study
Portfolio Pulse from
Biodesix has announced the publication of a clinical validation study for its Nodify CDT blood-based lung nodule test in the CHEST Pulmonary Journal. The study, involving 447 patients, reaffirms the test's performance.
January 07, 2025 | 11:15 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Biodesix's Nodify CDT test has been validated in a study published in the CHEST Pulmonary Journal, confirming its effectiveness in analyzing lung nodules.
The publication of a clinical validation study in a reputable journal like CHEST is a significant endorsement of Biodesix's Nodify CDT test. This reaffirms the test's performance and could lead to increased adoption and sales, positively impacting Biodesix's stock price.
CONFIDENCE 95
IMPORTANCE 80
RELEVANCE 90